ELOX (Eloxx Pharmaceuticals) Current Accrued Expense: $1.86 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELOX Eloxx Pharmaceuticals Inc ELOX
19 GF Score
Price $17.63
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals Current Accrued Expense?

Eloxx Pharmaceuticals ELOX -3.82% 19 Current Accrued Expense is $1.86 Mil as of Jun. 2026. GuruFocus rates ELOX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Eloxx Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1.86 Mil.

Eloxx Pharmaceuticals's quarterly Current Accrued Expense increased from Jun. 2025 ($0.00 Mil) to Mar. 2026 ($1.07 Mil) and increased from Mar. 2026 ($1.07 Mil) to Jun. 2026 ($1.86 Mil).

Eloxx Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2021 ($2.48 Mil) to Dec. 2022 ($1.90 Mil) and declined from Dec. 2022 ($1.90 Mil) to Dec. 2025 ($0.92 Mil).

Eloxx Pharmaceuticals Current Accrued Expense Related Terms

Eloxx Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Current Accrued Expense Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec18 Dec19 Dec20 Dec21 Dec22 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.36 1.51 2.48 1.90 0.92

Eloxx Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Jun25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 2.26 0.00 1.07 1.86
ELOX
19GF Score
Eloxx Pharmaceuticals Inc ELOX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.86 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Current Accrued Expense of $1.86 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Current Accrued Expense too high?
Eloxx Pharmaceuticals' current Current Accrued Expense is $1.86 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Current Accrued Expense compare to TCRX and MCRB?
Eloxx Pharmaceuticals' Current Accrued Expense of $1.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Current Accrued Expense is $1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Current Accrued Expense of $1.86 Mil. The current Current Accrued Expense is $1.86 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Current Accrued Expense is $1.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Other Exchanges J36:Germany
Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
19GF Score

Get the complete analysis for ELOX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.63
Price